Brent Warner, MBA

Brent Warner is President, Gene Therapy at Poseida Therapeutics. Before joining Poseida in February 2022, he was previously Vice President, Gene Therapy and Rare Disease at Novartis, where he was responsible for building and launching multiple gene therapies. His prior roles include serving as a U.S. commercial leader in Hemophilia A at BioMarin Pharmaceuticals, in a variety of strategic and operational roles at Biogen, and in commercial launch roles in blood disorders at Baxalta, now a wholly owned subsidiary of Takeda. Mr. Warner has an MBA with an emphasis in marketing and finance and a Bachelor of Business Administration degree, both from Northwood University in Michigan.